Alluvi, previously BI 4744, offers a promising development in obesity therapy. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable results in https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/